Precigen Yönetim
Yönetim kriter kontrolleri 4/4
Precigen CEO'su Helen Sabzevari, Jan2020 tarihinde atandı, in görev süresi 6.58 yıldır. in toplam yıllık tazminatı $ 5.35M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.7% maaş ve 81.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.05% ine doğrudan sahiptir ve bu hisseler $ 27.25M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.6 yıl ve 12.3 yıldır.
Anahtar bilgiler
Helen Sabzevari
İcra Kurulu Başkanı
US$5.4m
Toplam tazminat
| CEO maaş yüzdesi | 18.68% |
| CEO görev süresi | 6.6yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 6.6yrs |
| Yönetim Kurulu ortalama görev süresi | 12.3yrs |
Son yönetim güncellemeleri
Recent updates
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
Summary Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities. Key catalysts include EMA review of PRGN-2012 and PRGN-2009 data updates by the end of 2026, with break-even cash flow targeted by year-end. Read the full article on Seeking Alpha
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
Catalysts About Precigen Precigen is a biotechnology company focused on developing and commercializing immunotherapies, including PAPZIMEOS for adults with recurrent respiratory papillomatosis and pipeline programs such as PRGN-2009 that use its AdenoVerse platform. What are the underlying business or industry changes driving this perspective?
PGEN: Orphan Exclusivity And Early RRP Uptake Will Drive Future Upside
Analysts have lifted the Precigen fair value estimate from $12.45 to $14.50, citing higher Street price targets attributed to Papzimeos sales that have exceeded guidance and recent FDA orphan-drug exclusivity for the therapy. Analyst Commentary Recent Street research on Precigen centers on Papzimeos launch execution and the impact of FDA orphan-drug exclusivity on the company’s revenue potential and valuation framework.PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking AlphaPrecigen: Successful Proof Of Platform, But Cash Worries Remain
Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking AlphaWe're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$337m |
| Mar 31 2026 | n/a | n/a | -US$383m |
| Dec 31 2025 | US$5m | US$1m | -US$430m |
| Sep 30 2025 | n/a | n/a | -US$426m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$5m | US$1m | -US$126m |
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$135m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$4m | US$1m | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$3m | US$1m | -US$80m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$3m | US$1m | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$20m | US$1m | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$100m |
| Jun 30 2020 | n/a | n/a | -US$122m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$1m | US$500k | -US$169m |
Tazminat ve Piyasa: Helen 'ın toplam tazminatı ($USD 5.35M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.98M ).
Tazminat ve Kazançlar: Helen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Helen Sabzevari (64 yo)
Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.9m | |
| President | 6.6yrs | US$5.35m | 1.05% $ 27.2m | |
| Chief Financial Officer | 4.8yrs | US$1.49m | 0.071% $ 1.8m | |
| Chief Operating Officer | 6.5yrs | US$1.56m | 0.13% $ 3.4m | |
| Chief Legal Officer & Corporate Secretary | 15.6yrs | US$1.43m | 0.21% $ 5.5m | |
| Chief Commercial Officer | 2.1yrs | US$1.23m | 0.039% $ 1.0m | |
| VP & Head of Investor Relations | 8.6yrs | Veri yok | Veri yok | |
| Senior VP & Head of Research | no data | Veri yok | Veri yok | |
| Senior VP & Head of CMC | no data | Veri yok | Veri yok | |
| Senior VP & Head of Clinical Operations and Regulatory Affairs | 3.2yrs | Veri yok | Veri yok | |
| Chief Executive Officer of MBP Titan LLC | 7.6yrs | Veri yok | Veri yok |
Deneyimli Yönetim: PGEN 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.9m | |
| President | 6.2yrs | US$5.35m | 1.05% $ 27.2m | |
| Independent Director | 14.8yrs | US$319.00k | 0.056% $ 1.5m | |
| Independent Director | 10.2yrs | US$313.00k | 0.35% $ 9.0m | |
| Independent Director | 18.5yrs | US$312.50k | 0.22% $ 5.7m | |
| Lead Independent Director | 12.3yrs | US$312.50k | 0.19% $ 5.0m | |
| Independent Director | 18.5yrs | US$300.00k | 0.34% $ 8.9m | |
| Independent Director | 2.1yrs | US$306.50k | 0.085% $ 2.2m | |
| Independent Director | 9.3yrs | US$313.00k | 0.19% $ 4.8m |
Deneyimli Yönetim Kurulu: PGEN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/10 07:19 |
| Gün Sonu Hisse Fiyatı | 2026/08/10 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Precigen, Inc. 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |